These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10767583)

  • 1. The effect of rivastigmine on sleep in elderly healthy subjects.
    Schredl M; Weber B; Braus D; Gattaz WF; Berger M; Riemann D; Heuser I
    Exp Gerontol; 2000 Mar; 35(2):243-9. PubMed ID: 10767583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.
    Kaasinen V; Någren K; Järvenpää T; Roivainen A; Yu M; Oikonen V; Kurki T; Rinne JO
    J Clin Psychopharmacol; 2002 Dec; 22(6):615-20. PubMed ID: 12454562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.
    Polinsky RJ
    Clin Ther; 1998; 20(4):634-47. PubMed ID: 9737824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donepezil-induced REM sleep augmentation enhances memory performance in elderly, healthy persons.
    Schredl M; Weber B; Leins ML; Heuser I
    Exp Gerontol; 2001 Feb; 36(2):353-61. PubMed ID: 11226748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The reduced release of GH by GHRH in 8 subjects aged 65-69 years is augmented considerably by rivastigmine, a drug for Alzheimer's disease.
    Obermayr RP; Mayerhofer L; Knechtelsdorfer M; Tragl KH; Geyer G
    Gerontology; 2003; 49(3):191-5. PubMed ID: 12679611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the novel acetylcholinesterase inhibitor SDZ ENA 713 on sleep in man.
    Holsboer-Trachsler E; Hatzinger M; Stohler R; Hemmeter U; Gray J; Müller J; Kocher R; Spiegel R
    Neuropsychopharmacology; 1993 Jan; 8(1):87-92. PubMed ID: 8424849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
    Jann MW; Shirley KL; Small GW
    Clin Pharmacokinet; 2002; 41(10):719-39. PubMed ID: 12162759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.
    Suh DC; Arcona S; Thomas SK; Powers C; Rabinowicz AL; Shin H; Mirski D
    Drugs Aging; 2004; 21(6):395-403. PubMed ID: 15084141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivastigmine. A review of its use in Alzheimer's disease.
    Spencer CM; Noble S
    Drugs Aging; 1998 Nov; 13(5):391-411. PubMed ID: 9829166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatric symptoms, and sleep.
    Maclean LE; Collins CC; Byrne EJ
    Int Psychogeriatr; 2001 Sep; 13(3):277-88. PubMed ID: 11768375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testosterone mediates sex difference in hypothermia and cholinesterase inhibition by rivastigmine.
    Wang RH; Schorer-Apelbaum D; Weinstock M
    Eur J Pharmacol; 2001 Dec; 433(1):73-9. PubMed ID: 11755136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivastigmine-induced REM sleep behavior disorder (RBD) in a 88-year-old man with Alzheimer's disease.
    Yeh SB; Yeh PY; Schenck CH
    J Clin Sleep Med; 2010 Apr; 6(2):192-5. PubMed ID: 20411699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The new cholinesterase inhibitors for Alzheimer's disease, Part 2: illustrating their mechanisms of action.
    Stahl SM
    J Clin Psychiatry; 2000 Nov; 61(11):813-4. PubMed ID: 11105732
    [No Abstract]   [Full Text] [Related]  

  • 14. Cholinesterase inhibitor rivastigmine enhance the mitochondrial electron transport chain in lymphocytes of patients with Alzheimer's disease.
    Casademont J; Miró O; Rodriguez-Santiago B; Viedma P; Blesa R; Cardellach F
    J Neurol Sci; 2003 Jan; 206(1):23-6. PubMed ID: 12480080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
    Rakonczay Z
    Acta Biol Hung; 2003; 54(2):183-9. PubMed ID: 14535624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
    Auriacombe S; Pere JJ; Loria-Kanza Y; Vellas B
    Curr Med Res Opin; 2002; 18(3):129-38. PubMed ID: 12094822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine.
    Zhao Q; Tang XC
    Eur J Pharmacol; 2002 Nov; 455(2-3):101-7. PubMed ID: 12445575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
    Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivastigmine for Alzheimer's disease.
    Birks J; Iakovidou V; Tsolaki M
    Cochrane Database Syst Rev; 2000; (2):CD001191. PubMed ID: 10796621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans.
    Kennedy JS; Polinsky RJ; Johnson B; Loosen P; Enz A; Laplanche R; Schmidt D; Mancione LC; Parris WC; Ebert MH
    J Clin Psychopharmacol; 1999 Dec; 19(6):513-21. PubMed ID: 10587286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.